StockNews.AI
CRGX
StockNews.AI
41 days

CARGO THERAPEUTICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of CARGO Therapeutics, Inc. - CRGX

1. CARGO Therapeutics proposed sale to Concentra for $4.379 per share. 2. Investor inquiry about the adequacy of the sale price. 3. Contingent value rights linked to CARGO’s net cash and product dispositions. 4. Investigation focuses on possible undervaluation of CARGO. 5. Transaction structured as a tender offer with time sensitivity.

3m saved
Insight
Article

FAQ

Why Bullish?

While the sale price suggests a premium, potential undervaluation raises investor interest. Historical examples show that inquiries can improve stock price stability.

How important is it?

The investigation indicates possible shareholder concern over valuation, likely attracting attention and volatility.

Why Short Term?

This situation could lead to immediate trading volatility until the sale closes or is revised. Historical negotiations often affect short-term pricing.

Related Companies

CNCE
- NEW YORK CITY & NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana Charles C. Foti, Jr., Esq. and the law firm of Kahn Swick & Foti, LLC (“KSF”) are investigating the proposed sale of CARGO Therapeutics, Inc. (NasdaqGS: CRGX) to Concentra Biosciences, LLC. Under the terms of the proposed transaction, Concentra will acquire CARGO for $4.379 in cash per share, plus one non-transferable contingent value right, representing the right to receive: (i) 100% of the closing net cash of CARGO in excess of $217.5 million; and (ii) 80% of any net proceeds received within two years following closing from any disposition of certain of CARGO’s product candidates that occurs within two years following closing. KSF is seeking to determine whether this consideration and the process that led to it are adequate, or whether the consideration undervalues the Company. If you believe that this transaction undervalues the Company and/or if you would like to discuss your legal rights regarding the proposed sale, you may, without obligation or cost to you, e-mail or call KSF Managing Partner Lewis S. Kahn (lewis.kahn@ksfcounsel.com) toll free at any time at 855-768-1857, or visit https://www.ksfcounsel.com/cases/nasdaqgs-crgx/ to learn more. Please note that the transaction is structured as a tender offer, such that time may be of the essence. To learn more about KSF, whose partners include the Former Louisiana Attorney General, visit www.ksfcounsel.com. CONNECT WITH US: Facebook || Instagram || YouTube || TikTok || LinkedIn More News From Kahn Swick & Foti, LLC

Related News